Sunshine Biopharma Announces Share Repurchase Program
MONTREAL, Jan. 19, 2023 (GLOBE NEWSWIRE) -- Sunshine Biopharma Inc. (NASDAQ: “SBFM”), a pharmaceutical company offering and researching life-saving medicines...
Clinical Trial
Bellicum Pharmaceuticals to Present Early Phase 1 Results for BPX-601 in Prostate Cancer at ASCO 2023 Genitourinary Cancers Symposium
HOUSTON, Jan. 19, 2023 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (Nasdaq: BLCM), a leader in developing novel, controllable cellular immunotherapies...
Editas Medicine and Shoreline Biosciences Enter into Definitive Agreement for Shoreline to Acquire Editas’ iNK Cell Franchise and Related Gene Editing Technologies
Shoreline to obtain an exclusive license to SLEEK knock-in technology for iPSC-derived NK cells, an exclusive license to SLEEK for...
XORTX Announces Positive Topline Results from XRX-OXY-101 Clinical Trial
Safe and Effective Dosing of XORLO™CALGARY, Alberta, Jan. 19, 2023 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the “Company”)...
Amarin Responds to Inaccurate and Misleading Statement by Sarissa
-- Board Refreshment Process Has Been Comprehensive, Independent and Transparent; Sarissa’s Candidates Are Not Qualified Versus Recently Appointed Board Members...
InvestmentPitch Media Video Discusses FSD Pharma’s Submission of its Clinical Trial Application for Planned Phase-1 Trial for Lucid-MS, a Candidate for Treatment of MS
VANCOUVER, British Columbia, Jan. 19, 2023 (GLOBE NEWSWIRE) -- FSD Pharma Inc. (NASDAQ:HUGE) (CSE:HUGE) (FSE:0K9A), a biopharmaceutical company dedicated to...
PharmaTher Holdings Submits for FDA Orphan Drug Designation for Ketamine to Treat Rett Syndrome
TORONTO, Jan. 18, 2023 (GLOBE NEWSWIRE) -- PharmaTher Holdings Ltd. (the “Company” or “PharmaTher”) (OTCQB: PHRRF) (CSE: PHRM), a leader...
ORYZON Announces First Patient In in NET, a Collaborative Phase II Basket Study With Iadademstat in R/R Patients With Neuroendocrine Carcinomas
Collaborative study with Fox Chase Cancer Center Trial will assess the safety and efficacy of iadademstat in pulmonary and extrapulmonary...
SAB Biotherapeutics Receives an Additional $8.2 Million in Closeout of DoD Contract
SIOUX FALLS, S.D., Jan. 18, 2023 (GLOBE NEWSWIRE) -- SAB Biotherapeutics (Nasdaq: SABS), a clinical-stage biopharmaceutical company with a novel...
Pasithea Therapeutics Signs CMC Development and Manufacturing Agreement for the Production of PAS-004
-- Plans to Initiate a Phase 1 Clinical Trial in the U.S. for Neurofibromatosis Type 1 (NF1) in 2H 2023...
European Commission Grants Orphan Drug Designation for aTyr Pharma’s Efzofitimod for Treatment of Sarcoidosis
Global pivotal Phase 3 EFZO-FIT™ study in pulmonary sarcoidosis launched in EuropeSAN DIEGO, Jan. 18, 2023 (GLOBE NEWSWIRE) -- aTyr...
OpGen Provides Preliminary Unaudited Revenue for FY 2022 and Business Update
Preliminary full year revenue for 2022 of approximately $ 2.7 million is within most recent guidance rangeCash position as of...
KemPharm Partners with the Hypersomnia Foundation to Support Sleep Disorder Research and Advocacy
KemPharm advancing multicenter Phase 2 clinical trial investigating the efficacy and safety of KP1077 for the treatment of idiopathic hypersomnia...
SciSparc Receives Approval to Conduct its Clinical Trial in Children with Autism Spectrum Disorder at the Soroka Medical Center
The Company has already secured approvals from Ethics Committee and Israeli Ministry of Health for the Company's study with its proprietary SCI-210 treatment TEL AVIV, Israel, Jan. 18,...
AC Immune Partner Life Molecular Imaging Initiates Phase 3 Study of Tau PET Diagnostic PI-2620 for Alzheimer’s Disease
AC Immune Partner Life Molecular Imaging Initiates Phase 3 Study of Tau PET Diagnostic PI-2620 for Alzheimer’s Disease First Alzheimer’s...
Plus Therapeutics Announces First Patient Dosed in ReSPECT-GBM Phase 2b Trial of Rhenium (186Re) Obisbemeda for Treatment of Recurrent Glioblastoma
Figure Initial treatment imaging from first patient treated in the ReSPECT-GBM Phase 2b trialAUSTIN, Texas, Jan. 18, 2023 (GLOBE NEWSWIRE)...
Monopar Announces Successful Advancement of Camsirubicin Phase 1b Clinical Trial Past Fourth Cohort, Escalates Next to 650mg/m2
WILMETTE, Ill., Jan. 18, 2023 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company focused on developing...
Krystal Biotech Receives European Commission Orphan Designation for KB407 for the Treatment of Cystic Fibrosis
PITTSBURGH, Jan. 18, 2023 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS), a biotechnology company focused on developing...
Quris-AI and MBZUAI to launch world-class Bio-AI center in Abu-Dhabi
Abu Dhabi-based collaboration to focus on accelerating the development of new personalized medications using AIABU DHABI, United Arab Emirates, Jan....
US Department of Defense Uniformed Services University Clinical Evaluation of Travelan™ Achieves 150 Recruitment Milestone
Highlights: First participants enrolled in USU Travelan Clinical Trial Field Study157 participants successfully randomized into the Clinical StudyPlans in place...